secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000950170-22-007835
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022
-------------------------------------------------------------------------

- Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.
- Total revenue $17.1M for Q1 2022, up from $16.0M in Q1 2021, primarily from AbbVie collaboration.
- R&D expenses $30.6M (up $8.2M YoY); G&A $10.5M (up $1.3M YoY); operating loss implied.
- Phase 2 praluzatamab ravtansine: Arm A enrollment complete; initial data for Arms A & B in H2 2022.
- CX-2029 completed enrollment in squamous NSCLC cohort; data update expected in H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/0000950170-22-007835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017022007835/ctmx-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer